Cancer Family
Carcinoma
CI-CAN-00000114Explore in graph →
7,371 active trials118 approved drugs1,150 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000114Explore in graph →
Clinical trials
25,734 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3,407)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04864054 | GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC(ARYA-3) | recruiting | Phase 1 / Phase 2 | 60 | Eureka Therapeutics Inc.INDUSTRY | 2 | Sep 10, 2026 | clinicaltrials |
| NCT05762536 | Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC(DAROTAXEL) | recruiting | Phase 2 | 245 | Erasmus Medical CenterOTHER | 1 | Sep 10, 2026 |
| NCT05766371 | Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer | recruiting | Phase 2 | 48 | University of California, San FranciscoOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT05946213 | Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer | recruiting | Phase 3 | 1,209 | NRG OncologyOTHER | 4 | Sep 10, 2026 | clinicaltrials |
| NCT06040125 | Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial | recruiting | N/A | 80 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06040762 | A Home-Based Prehabilitation Exercise Intervention for Improving Physical Function in Patients With Bladder Cancer and Upper Tract Urothelial Cancer, Get Moving Trial | recruiting | N/A | 128 | University of WashingtonOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06100705 | Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC | recruiting | Phase 2 | 26 | Yale UniversityOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06266299 | A Study of KK2269 in Adult Participants With Solid Tumors | recruiting | Phase 1 | 101 | Kyowa Kirin Co., Ltd.INDUSTRY | 2 | Sep 10, 2026 | clinicaltrials |
| NCT06293898 | Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors | recruiting | Phase 1 | 280 | SystImmune Inc.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06524973 | Telehealth Self-Management Coaching Sessions to Improve Quality of Life in Pancreatic Cancer Survivors and Their Family Care Givers | recruiting | N/A | 136 | City of Hope Medical CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06563947 | Oral Fecal Microbiota Transplantation in Advanced Hepatocellular Carcinoma After Progression on ICI-TKI Therapy | recruiting | Phase 2 | 30 | Xu Yong, MDOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07000253 | Timing of Comprehensive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma(OMEC-5) | recruiting | Phase 2 | 290 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 3 | Sep 10, 2026 | clinicaltrials |
| NCT07026474 | Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC(RePaIr-HN) | recruiting | Phase 3 | 214 | Universität des SaarlandesOTHER | 2 | Sep 10, 2026 | clinicaltrials |
| NCT07161869 | Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma (POELH-III)(POELH-III) | recruiting | — | 250 | Erasmus Medical CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07215364 | Impact of Exercise on Quality of Life of EBC Patients on Treatment With Adjuvant AI With or Without CDK4/6 Inhibitors(EX-AI) | recruiting | N/A | 74 | Spanish Breast Cancer Research GroupOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07416123 | A Study of GEN1106 in Participants With Solid Tumors | recruiting | Phase 1 | 103 | GenmabINDUSTRY | 3 | Sep 10, 2026 | clinicaltrials |
| NCT07462377 | A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC | recruiting | Phase 1 | 110 | EpiBiologicsINDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07638852 | Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM.(ABC-R) | recruiting | Phase 2 | 58 | Fudan UniversityOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07640789 | A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08) | recruiting | Phase 3 | 418 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07652242 | Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer(VITAL-TNBC) | recruiting | Phase 1 | 60 | Immunomic Therapeutics, Inc.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07677774 | GPC3-Targeted PET/CT in Hepatocellular Carcinoma | recruiting | N/A | 40 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07780838 | Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma | recruiting | Phase 2 | 29 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07811752 | Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal Cancer | recruiting | Phase 2 | 28 | Shanghai Chest HospitalOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07812805 | SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors | recruiting | Phase 1 | 100 | SK Life Science, Inc.INDUSTRY | 2 | Sep 10, 2026 | clinicaltrials |
| NCT07814014 | Real-world Insight Into Systemic Therapies for HCC: Single-center Study(HCC) | recruiting | — | 1,000 | Mansoura UniversityOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT03606967 | Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer | recruiting | Phase 2 | 86 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT04899908 | Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases | recruiting | Phase 2 | 134 | Brigham and Women's HospitalOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05570253 | A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer | recruiting | Phase 2 | 55 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05774899 | CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC | recruiting | Phase 1 / Phase 2 | 32 | Michael J. Dennis, MDOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05985681 | Testing RG1-VLP Vaccine to Prevent HPV-related Cancers | recruiting | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06037980 | CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence(PURITY) | recruiting | Phase 2 / Phase 3 | 300 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06097962 | Safety and Efficacy of NK510 to Treat NSCLC | recruiting | Early Phase 1 | 12 | Base Therapeutics (Shanghai) Co., Ltd.INDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06175845 | Endoscopic Radiofrequency Ablation for Unresectable Cholangiocarcinoma(ACTICCA-2) | recruiting | N/A | 130 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06184516 | Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy | recruiting | Phase 2 | 127 | University of FloridaOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06253871 | A Phase 1/1b Study of IAM1363 in HER2 Cancers | recruiting | Phase 1 | 383 | Iambic Therapeutics, IncINDUSTRY | 8 | Sep 9, 2026 | clinicaltrials |
| NCT06315010 | Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis(REPOSE) | recruiting | Phase 2 | 20 | MedSIROTHER | 3 | Sep 9, 2026 | clinicaltrials |
| NCT06440005 | A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 80 | Angiex, Inc.INDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06597721 | ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours | recruiting | Phase 1 | 210 | Adcendo ApSINDUSTRY | 2 | Sep 9, 2026 | clinicaltrials |
| NCT06696768 | Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer | recruiting | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06780137 | A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002) | recruiting | Phase 1 / Phase 2 | 327 | Merck Sharp & Dohme LLCINDUSTRY | 12 | Sep 9, 2026 | clinicaltrials |
| NCT07147231 | Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer | recruiting | Phase 1 / Phase 2 | 86 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07272083 | New Diagnostic Criteria in the Evaluation Response to Ablation Treatment of Hepatocellular Carcinoma Nodules(CEUS_LR_TRA) | recruiting | — | 200 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07310056 | The Construction and Clinical Application of an Integrated Perioperative Management System for Lung Cancer Based on Wearable Devices and Intelligent Platforms | recruiting | N/A | 126 | West China HospitalOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07541170 | A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)(KRASCENDO 3) | recruiting | Phase 3 | 400 | Hoffmann-La RocheINDUSTRY | 6 | Sep 9, 2026 | clinicaltrials |
Data updated 21 days agoSource updated Sep 10, 2026source: clinicaltrials